510 related articles for article (PubMed ID: 25078674)
1. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
2. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
[TBL] [Abstract][Full Text] [Related]
3. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
4. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
Sardar M; Recio-Boiles A; Mody K; Karime C; Chandana SR; Mahadevan D; Starr J; Jones J; Borad M; Babiker H
Expert Opin Pharmacother; 2022 Dec; 23(18):2079-2089. PubMed ID: 36394449
[TBL] [Abstract][Full Text] [Related]
6. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma.
Mitsunaga S; Kasamatsu E; Machii K
Support Care Cancer; 2020 Nov; 28(11):5271-5279. PubMed ID: 32103356
[TBL] [Abstract][Full Text] [Related]
7. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
8. New Advances in the Treatment of Metastatic Pancreatic Cancer.
Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
[TBL] [Abstract][Full Text] [Related]
9. Orthotopic model of human pancreatic ductal adenocarcinoma and cancer cachexia in nude mice.
Jones-Bolin S; Ruggeri B
Curr Protoc Pharmacol; 2007 Jun; Chapter 14():Unit 14.3. PubMed ID: 21948162
[TBL] [Abstract][Full Text] [Related]
10. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
11. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
15. Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review.
Ruff SM; Pawlik TM
Front Biosci (Landmark Ed); 2024 Mar; 29(3):101. PubMed ID: 38538278
[TBL] [Abstract][Full Text] [Related]
16. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of treatments for pancreatic cancer.
El Hassouni B; Li Petri G; Liu DSK; Cascioferro S; Parrino B; Hassan W; Diana P; Ali A; Frampton AE; Giovannetti E
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):437-447. PubMed ID: 31100206
[No Abstract] [Full Text] [Related]
18. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
Lemstrova R; Melichar B; Mohelnikova-Duchonova B
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
[TBL] [Abstract][Full Text] [Related]
20. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
